A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult
A phase 2 trial of Mirvetuximab soravtansine, Bevacizumab, Carboplatin in ovarian cancer, run by AbbVie, now recruiting.
Overview
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer is a phase 2 interventional study registered as NCT07059845 by AbbVie, with 400 participants planned, started 2025-11-13 and due to reach its primary completion in 2029-01. Interventions recorded: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin.
- TrialMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Ovarian cancer.
- TrialA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Shares Mirvetuximab soravtansine, Carboplatin, Ovarian cancer.
- TrialA Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Shares Mirvetuximab soravtansine, Ovarian cancer.